Compare Pfizer Inc (PFE) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Invesco Preferred ETF — how do they compare? Pfizer Inc trades at $27.93 (market cap $158.56B), while Invesco Preferred ETF trades at $10.03 (market cap $3.60B). The key difference: Pfizer Inc is far larger — about 44× Invesco Preferred ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Invesco Preferred ETF for 94 Days on average.
| PFE | PGX | |
|---|---|---|
Market Cap | $158.56B | $3.60B |
Volume | 44,138,282 | 5,986,026 |
Sector | Health | — |
52-Week High | $29.02 | $11.61 |
52-Week Low | $23.67 | $9.97 |
Typical Hold Time | 158 Days | 94 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
PGX trades at $9.97, down 0.89% today, with technical indicators showing a bearish trend from moving averages but oversold signals from the RSI. The stock faces pressure amid mixed sentiment, with key support and resistance levels clustered around $10. Recent corporate actions include scheduled dividends for July and September 2026, but fundamental data such as P/E and profitability metrics are unavailable for analysis.
The outlook for PGX is cautious due to the bearish technical setup and lack of current fundamental visibility. Risks include potential volatility near the $10 level and dependence on future financial disclosures to assess valuation. Investment opportunity hinges on upcoming earnings reports clarifying growth and margins, while sentiment remains divided amid limited recent news coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
